Syros Pharmaceuticals SYRS Stock Price Today

To see all exchange delays and terms of use please see Barchart’s disclaimer. The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction. Live educational sessions using site features to explore today’s markets. Realtime quote and/or trades are not sourced from all markets. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

Other market data may be delayed by 15 minutes or more. Syros Pharmaceuticals, Inc. delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s… Syros Pharmaceuticals, Inc. delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022.

Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Syros Pharmaceuticals in the last twelve months.

• 48.77% of the stock of Syros Pharmaceuticals is held by institutions.
• The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.
• Barchart is committed to ensuring digital accessibility for individuals with disabilities.
• The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.

Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns.

Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company.

SYRS Stock – Frequently Asked Questions

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days.

Bloomberg Markets The Close Romaine Bostick breaks down the day’s top stories and trading action leading into the close. The 3 year net cashflow from operations growth rate now stands at -84.69%. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

SYRS- Potential beginning of the bullish trendFollow me and smash that like button! Bio-pharmaceutical company aims to treat cancer and genetic diseases. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time.

The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Syros Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Syros Pharmaceuticals stock price target cut to $10 from $14 at Alliance Global

Data may be intentionally delayed pursuant to supplier requirements. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world. Verify your identity, personalize the content you receive, or create and administer your account.

The formula for calculating should i buy a house without realtor yield is to divide the annual dividend paid per share by the stock price. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The volatility of SYROS PHARMACEUTICALS INC’s share price is greater than that of 92.92% US stocks with at least 200 days of trading history. Exchanges report short interest twice a month.Percent of FloatTotal short positions relative to the number of shares available to trade.

In the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock. Only 2 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Right-click on the chart to open the Interactive Chart menu. Market flag for targeted data from your country of choice. For US and Canadian Stocks, the Overview page includes key statistics on the stock’s fundamentals, with a link to see more.

• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
• According to analysts’ consensus price target of $32.80, Syros Pharmaceuticals has a forecasted upside of 941.3% from its current price of $3.15.
• Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter.
• An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia . The average analyst rating for SYRS stock from 5 stock analysts is “Strong Buy”. This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Key Data

From media and technology to finance and real estate, leagues and teams across the globe have matured into far more than just back page entertainment. And the decisions they make have huge consequences, not just for the bottom line, but for communities, cities, even entire countries. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

The latest trend in earnings estimate revisions may not translate into furthe… © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed.

There may be delays, omissions, or inaccuracies in the Information. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

Raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. Syros Pharmaceuticals’ stock was trading at $3.59 at the beginning of 2023. Since then, SYRS stock has decreased by 16.7% and is now trading at $2.99.

Only 7 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days. MarketBeat has tracked 1 news article for Syros Pharmaceuticals this week, compared to 1 article on an average week. Syros Pharmaceuticals has received a 71.05% net impact score from Upright.

Overview

One share of SYRS stock can currently be purchased for approximately $2.99. 48.77% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. 12.79% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The company was founded in 2011 and is based in Cambridge, Massachusetts.

This popular ETF stands apart from its peers with unusually large ownership of many stocks in its compact portfolio. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Syros Pharmaceuticals Inc. 52 week high is $11.50 as of April 28, 2023.

Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Since 1988 it has more than doubled the S&P 500 with an https://1investing.in/ gain of +24.48% per year. These returns cover a period from January 1, 1988 through March 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.